BioPharmSignal logoBioPharmSignal

Biotech News

Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026

Insmed (INSM)InsmedEarnings

INSM (INSM) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is insm.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

INSMInsmed2026-07-23 11:00 EST

Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026

INSMInsmed2026-05-07 11:00 EST

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

XAIRBeyond Air2026-08-04 12:00 EST

Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026

PULMPulmatrix2026-05-15 12:20 EST

Pulmatrix Announces First Quarter 2026 Financial Results

RVPHReviva Pharmaceuticals2026-05-13 20:35 EST

Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights

TBPHTheravance Biopharma2026-05-07 12:30 EST

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

VERUVeru2026-05-06 12:30 EST

Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th

LUNGPulmonx2026-04-29 20:05 EST

Pulmonx Reports First Quarter 2026 Financial Results

LUNGPulmonx2026-04-15 20:05 EST

Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026

VERUVeru Inc2026-02-11 11:30 EST

Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

View all latest news

Insmed

Serious and Rare Diseases Insmed develops and commercializes therapies for serious pulmonary and rare diseases. Its portfolio combines marketed respiratory medicines with late-stage inhaled therapies and earlier gene-therapy programs. Commercial Respiratory Portfolio BRINSUPRI, or brensocatib, is a DPP1 inhibitor for non-cystic-fibrosis...

Recent company news

INSMInsmed2026-08-06 11:00 EST

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update

INSMInsmed2026-07-23 11:00 EST

Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026

INSMInsmed2026-07-16 11:00 EST

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension

INSMInsmed2026-06-23 11:00 EST

Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory

INSMInsmed2026-06-04 11:00 EST

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Stock data

Close
132.55 USD
Market cap
22.48B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States